Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on June 2, 2009, covering events occurring on June 1, 2009. The filing serves as a Regulation FD disclosure regarding upcoming management presentations at industry conferences.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces scheduled speaking engagements by company executives.
Guidance, Outlook, and Management Commentary
Management has scheduled the following presentations to discuss the company's progress:
- Dr. David Aviezer (President and CEO): Presenting at the 8th Annual Needham Life Sciences Conference in New York on June 10, 2009, and the 8th National Life Science and Technology Week ISLI-Biomed Israel 2009 on June 15, 2009.
- Dr. Einat Brill Almon (Senior Vice President of Product Development): Presenting at the 3rd International Conference on Plant-Based Vaccines & Antibodies in Italy on June 16, 2009.
An audio webcast of Dr. Aviezer's presentation at the Needham conference will be available on the company website.
Key Facts for Investor Verification
- Verify the content of the press release dated June 1, 2009, attached as Exhibit 99.1.
- Confirm the availability of the audio webcast for the June 10, 2009, Needham Life Sciences Conference on the company website.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial performance.